论文部分内容阅读
[目的]探讨表皮生长因子受体(EGFR)和血管内皮生长因子(VEGF)在不同级别的胶质瘤中的表达水平,并研究表达水平是否能用于指导预后判断和治疗方法的选择。[方法]对56例手术后胶质瘤患者的石蜡切片组织进行免疫组织化学检测;根据EGFR和VEGF表达水平分析胶质瘤患者治疗后的远期疗效。[结果]在8例Ⅰ和Ⅱ级胶质瘤中,EGFR和VEGF阳性表达率分别为37.5%(3例)和25.0%(2例),在48例Ⅲ和Ⅳ级胶质瘤中分别为70.8%(34例)和79.2%(41例),其P值分别为0.065和0.005。在48例Ⅲ和Ⅳ级胶质瘤中,EGFR阴性和阳性患者1年、2年、3年生存率分别为57.1%、39.2%、19.6%和56.4%、31.7%、9.9%,两组生存率比较χ2=0.243,P=0.622,中位生存期分别13.8个月和16.4个月;VEGF阴性和阳性患者1年、2年、3年生存率分别为60.0%、45.0%、22.5%和58.5%、21.3%、14.2%(χ2=0.210,P=0.646),中位生存期分别19.6个月和15.3个月。[结论]EGFR和VEGF阳性表达率随着胶质瘤的恶性程度增加而增加,尚不能根据EGFR、VEGF表达水平指导判断胶质瘤的预后和指导治疗的选择。
[Objective] To investigate the expression of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) in different grades of gliomas and to study whether the expression level can be used to guide the prognosis and treatment options. [Method] Immunohistochemistry was performed on paraffin sections of 56 patients with glioma after operation. The long-term efficacy of glioma patients was analyzed according to the expression of EGFR and VEGF. [Results] The positive rates of EGFR and VEGF in 8 cases of grade I and II gliomas were 37.5% (3 cases) and 25.0% (2 cases), respectively. In 48 cases of grade III and IV gliomas, the positive rates of EGFR and VEGF were 70.8% (34 cases) and 79.2% (41 cases), the P values were 0.065 and 0.005, respectively. In 48 cases of grade III and IV gliomas, the 1-year, 2-year and 3-year survival rates of EGFR negative and positive patients were 57.1%, 39.2%, 19.6% and 56.4%, 31.7% and 9.9% The median survival time was 13.8 months and 16.4 months respectively. The 1-year, 2-year and 3-year survival rates of patients with negative and positive VEGF were 60.0%, 45.0%, 22.5% and 58.5 %, 21.3%, 14.2% respectively (χ2 = 0.210, P = 0.646). The median survival time was 19.6 months and 15.3 months respectively. [Conclusion] The positive rates of EGFR and VEGF are increased with the malignant degree of glioma. The prognosis of glioma and the choice of guiding therapy can not be judged according to the expression of EGFR and VEGF.